These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 9883011)

  • 1. Experimental immunomodulatory therapy of inflammatory bowel disease.
    Schreiber S
    Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the mucosal immune system in inflammatory bowel disease.
    MacDermott RP
    J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease.
    Woywodt A; Ludwig D; Neustock P; Kruse A; Schwarting K; Jantschek G; Kirchner H; Stange EF
    Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):267-76. PubMed ID: 10333199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
    van Hogezand RA; Verspaget HW
    Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunopathogenesis of inflammatory bowel diseases].
    Neurath MF; Schürmann G
    Chirurg; 2000 Jan; 71(1):30-40. PubMed ID: 10662999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
    Ogata H; Hibi T
    Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytokines in the pathogenesis of inflammatory bowel disease.
    Papadakis KA; Targan SR
    Annu Rev Med; 2000; 51():289-98. PubMed ID: 10774465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines in inflammatory bowel disease.
    Kmieć Z
    Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D; Sémana G; Gosselin M; Bretagne MG
    Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
    Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
    Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
    Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
    Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The cytokines in inflammatory bowel disease].
    Polińska B; Matowicka-Karna J; Kemona H
    Postepy Hig Med Dosw (Online); 2009 Aug; 63():389-94. PubMed ID: 19724079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic targeting in the treatment of inflammatory bowel diseases.
    Bosani M; Ardizzone S; Porro GB
    Biologics; 2009; 3():77-97. PubMed ID: 19707398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway-based approaches to the treatment of inflammatory bowel disease.
    Bamias G; Pizarro TT; Cominelli F
    Transl Res; 2016 Jan; 167(1):104-15. PubMed ID: 26408803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.